Share Email Print

Proceedings Paper

Elucidation of the role of biological factors and device design in cerebral NIRS using an in vivo hematoma model based on high-intensity focused ultrasound
Author(s): Jianting Wang; Stanley Huang; Matthew Myers; Yu Chen; Cristin Welle; Joshua Pfefer
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Near‐Infrared Spectroscopy (NIRS) is an emerging medical countermeasure for rapid, field detection of hematomas caused by traumatic brain injury (TBI). Bench and animal tests to determine NIRS sensitivity and specificity are needed. However, current animal models involving non-invasively induced, localized neural damage are limited. We investigated an in vivo murine hematoma model in which cerebral hemorrhage was induced noninvasively by high-intensity focused ultrasound (HIFU) with calibrated positioning and parameters. To characterize the morphology of induced hematomas, we used skull-intact histological evaluation. A multi-wavelength fiber-optic NIRS system with three source-detector separation distances was used to detect hematoma A 1.1 MHz transducer produced consistent small-to-medium hematoma localized to a single hemisphere, along with bruising of the scalp, with a low mortality rate. A 220 kHz transducer produced larger, more diffuse hematomas, with higher variability in size and a correspondingly higher mortality rate. No skin bruising or blood accumulation between the skin and skull was observed following injury application with the 220 kHz transducer. Histological analysis showed higher sensitivity for larger hematomas (>4x4 mm2). NIRS optical density change after HIFU was able to detect all hematomas, with sensitivity dependent on wavelength and separation distance. While improvements in methods for validating cerebral blood distribution are needed, the HIFU hematoma model provided useful insights that will inform development of biologically relevant, performance test methods for cerebral NIRS systems.

Paper Details

Date Published: 21 March 2016
PDF: 8 pages
Proc. SPIE 9690, Clinical and Translational Neurophotonics; Neural Imaging and Sensing; and Optogenetics and Optical Manipulation, 96900U (21 March 2016); doi: 10.1117/12.2217771
Show Author Affiliations
Jianting Wang, U.S. Food and Drug Administration (United States)
Stanley Huang, U.S. Food and Drug Administration (United States)
Matthew Myers, U.S. Food and Drug Administration (United States)
Yu Chen, Univ. of Maryland, College Park (United States)
Cristin Welle, U.S. Food and Drug Administration (United States)
Joshua Pfefer, U.S. Food and Drug Administration (United States)

Published in SPIE Proceedings Vol. 9690:
Clinical and Translational Neurophotonics; Neural Imaging and Sensing; and Optogenetics and Optical Manipulation
Steen J. Madsen; E. Duco Jansen; Samarendra K. Mohanty; Nitish V. Thakor; Qingming Luo; Victor X. D. Yang, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?